Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Eligible subjects will be randomly assigned to one of three dose regimens of oral R115866 or
placebo for the treatment of severe plaque psoriasis for 12 twelve weeks. The safety and
efficacy of R115866 will be evaluated during the treatment period and the 8-week post
treatment follow-up period.